Proceeds Purposes The investment round will support continuation of clinical activities and acceleration of market development for the everlinQ endoAVF System, a catheter-based technology designed to create hemodialysis access for chronic kidney disease patients in a minimally invasive procedure. Funds will support the ongoing Novel Endovascular Access Trial (NEAT) clinical study (12-month follow up to complete in 2016) and additional global clinical research, as well as device reimbursement and market access initiatives.